Highest-materiality recent filing
Intensity Therapeutics Q1 net loss $2.4M; cash $10.2M; resumes trial enrollment
Net loss $2.4M for Q1 2026 vs $3.3M in Q1 2025; R&D expenses fell to $1.2M from $2.2M.
Intensity Therapeutics 2025 net loss $11.6M; cash $11.9M; TNBC trial pCR 71% vs 33%
Net loss narrowed to $11.6M from $16.3M in 2024; R&D spend fell to $6.8M from $10.5M.
Intensity Therapeutics expands at-the-market offering capacity to $60 million
Filed prospectus supplement on March 23, 2026 to increase ATM program from prior cap to $60.0 million aggregate.
Intensity Therapeutics regains Nasdaq minimum bid price compliance
Nasdaq confirmed compliance with $1.00 minimum bid price after 10 consecutive business days (Feb 19–Mar 4, 2026).
Intensity Therapeutics updates investor slide with preliminary FY2025 financial highlights
Slide dated March 4, 2026, presents unaudited financial highlights through December 31, 2025.
Reverse split at 1-for-25 effective 4:01 p.m. ET Feb 18, 2026; post-split trading begins Feb 19.
Intensity Therapeutics receives Nasdaq extension until June 1, 2026 to meet $1 bid price rule
Received 180-day extension from Nasdaq to June 1, 2026 to regain compliance with $1.00 minimum bid price rule.
Intensity Therapeutics increases ATM offering capacity to $30M
Filed prospectus supplement to raise ATM program capacity to $30 million.
Intensity Therapeutics Q3 net loss $2.7M; pauses two trials, extends cash runway to Q1 2027
Net loss $2.7M for Q3 2025 vs $3.5M YoY; cash $7.1M at Sept 30, plus $6.1M raised in Q4 2025.
Intensity Therapeutics prices $4M registered direct offering of 5M shares at $0.80
Gross proceeds of $4.0M from sale of 5M shares at $0.80 per share; closing expected Nov 3, 2025.
Intensity Therapeutics shareholders approve reverse stock split ratio of 1:5 to 1:30
Reverse split proposal passed with 18,333,570 For, 4,508,502 Against, 27,490 Abstain.
First patient in Cohort A achieved pathological complete response after two INT230-6 doses plus immunochemotherapy.
Bylaws amended to require one-third voting power for quorum (down from majority).
Intensity Therapeutics raises $11.3M, extends cash runway to H2 2026; Q2 net loss narrows to $2.5M
Net proceeds of ~$10.1M from two public offerings and ATM; cash runway now into H2 2026.
Intensity Therapeutics raises $6.6M via ATM stock sales; cash runway extended to H2 2026
Gross proceeds of $6.6M ($6.3M net) from sale of 19,868,658 shares at avg $0.3323/share in July 2025.
Intensity Therapeutics annual meeting results: director elected, auditor ratified
Mark A. Goldberg elected Class II director with 6,979,703 votes For, 222,974 Withheld.
Intensity Therapeutics raises ~$1.9M net in $0.30/share public offering for clinical studies
Gross proceeds $2,002,500 from 6,675,000 shares at $0.30/share; underwriter exercised over-allotment for 1,001,250 additional shares.
Intensity Therapeutics receives Nasdaq minimum bid price deficiency notice
Nasdaq notified INTS on June 6, 2025 that bid price was below $1.00 for 30 consecutive business days.
Intensity Therapeutics receives Nasdaq non-compliance notice for stockholders' equity
Nasdaq notified company on May 19, 2025 of failure to meet minimum $2.5M stockholders' equity requirement.
Intensity Therapeutics pauses Phase 3 sarcoma study enrollment; Q1 net loss $3.3M, cash $0.9M
Paused new site activations and enrollment in Phase 3 INVINCIBLE-3 sarcoma study due to funding constraints; 23 patients enrolled.
Intensity Therapeutics prices $2.35M public offering of common stock and warrants
3,133,333 shares and two series of warrants priced at $0.75 per unit; gross proceeds ~$2.35M.
Intensity Therapeutics posts Q2 2025 corporate presentation; no new material data disclosed
Presentation references lead candidate INT230-6 and DfuseRx platform for solid tumor treatment.
Intensity Therapeutics reports 2024 net loss of $16.3M; cash $2.6M; trial enrollment ongoing
Net loss of $16.3M for FY2024 vs $10.5M in 2023; R&D expenses rose to $10.5M from $4.8M.
Intensity Therapeutics prices $3M registered direct offering and warrants
Sold 1,237,113 shares at $2.425/share for gross proceeds of ~$3M.
Intensity Therapeutics Q3 net loss $3.5M; first patient dosed in Phase 2 TNBC study
Net loss of $3.5M for Q3 2024 vs $2.3M a year ago; R&D expenses rose to $2.2M.
Options to CFO Joseph Talamo cover 427,379 shares; to Principal Accounting Officer John Wesolowski cover 70,028 shares.
Intensity Therapeutics doses first patient in Phase 3 sarcoma trial; cash $6.3M into Q1 2025
First patient dosed in Phase 3 INVINCIBLE-3 study of INT230-6 vs SOC in soft tissue sarcoma; plans 333 patients.
Intensity Therapeutics stockholders approve ESPP and re-elect directors at annual meeting
8,522,632 shares represented (~62.15% quorum) at July 17, 2024 annual meeting.
Intensity Therapeutics enters $15M at-the-market equity offering with H.C. Wainwright
Up to $15M of common stock may be sold from time to time via ATM sales agent.
Intensity Therapeutics removes James Ahlers as officer; stays as consultant
James Ahlers removed as officer effective May 21, 2024 per board resolution.
Intensity Therapeutics appoints Thomas Dubin to Board, restores Audit Committee compliance
Thomas I. H. Dubin appointed as Class I director, expanding Board from 4 to 5 members.
Intensity Therapeutics enters collaboration with SAKK for Phase 2 breast cancer study of INT230-6
SAKK to conduct Phase 2 of INVINCIBLE-4 Study testing INT230-6 plus standard of care vs standard of care alone in neoadjuvant triple negative breast cancer in Europe.
Intensity Therapeutics Q1 net loss $4.6M; cash $10.5M funds operations into Q1 2025
Net loss of $4.6M in Q1 2024 vs $1.3M in Q1 2023; R&D expenses rose to $2.8M from $0.8M, G&A to $1.9M from $0.5M.
Daniel Donovan resigned from audit committee on April 12, 2024, leaving only 2 members; company received Nasdaq deficiency letter on April 18, 2024.
Intensity Therapeutics FY 2023 net loss $10.5M; cash $14.8M funds ops through Q1 2025
Net loss $10.5M in 2023 vs $7.6M in 2022; includes $2.3M non-cash loss on debt conversion.
On May 21, 2024, the Board of Directors of Intensity Therapeutics, Inc. (the “Company”) resolved that Mr. James Ahlers (i) shall be removed as an officer of the Company pursuant to the Company’s bylaws
appointed Thomas I. H. Dubin to the Board as a Class I director.
Max materiality 0.85 · Median 0.60 · Most common event other_material